- Home
- EVAX vs CERO Comparison
EVAX vs CERO Comparison
Compare EVAX & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CERO
- Stock Information
- Founded
- EVAX 2008
- CERO 2017
- Country
- EVAX Denmark
- CERO United States
- Employees
- EVAX N/A
- CERO N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CERO
- Sector
- EVAX Health Care
- CERO
- Exchange
- EVAX Nasdaq
- CERO Nasdaq
- Market Cap
- EVAX 8.7M
- CERO 8.4M
- IPO Year
- EVAX 2021
- CERO N/A
- Fundamental
- Price
- EVAX $0.89
- CERO $0.05
- Analyst Decision
- EVAX Strong Buy
- CERO
- Analyst Count
- EVAX 2
- CERO 0
- Target Price
- EVAX $11.00
- CERO N/A
- AVG Volume (30 Days)
- EVAX 82.5K
- CERO 35.8M
- Earning Date
- EVAX 10-31-2024
- CERO 11-19-2024
- Dividend Yield
- EVAX N/A
- CERO N/A
- EPS Growth
- EVAX N/A
- CERO N/A
- EPS
- EVAX N/A
- CERO N/A
- Revenue
- EVAX $3,295,000.00
- CERO N/A
- Revenue This Year
- EVAX $4,845.21
- CERO N/A
- Revenue Next Year
- EVAX $30.30
- CERO N/A
- P/E Ratio
- EVAX N/A
- CERO N/A
- Revenue Growth
- EVAX N/A
- CERO N/A
- 52 Week Low
- EVAX $0.85
- CERO $0.05
- 52 Week High
- EVAX $13.61
- CERO $12.80
- Technical
- Relative Strength Index (RSI)
- EVAX 21.83
- CERO 35.97
- Support Level
- EVAX $0.85
- CERO $0.05
- Resistance Level
- EVAX $0.96
- CERO $0.09
- Average True Range (ATR)
- EVAX 0.15
- CERO 0.02
- MACD
- EVAX -0.00
- CERO -0.01
- Stochastic Oscillator
- EVAX 5.75
- CERO 4.34
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.